GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

The findings could help clinicians use neuropsychiatric symptoms to prepare patients and families for a type of dementia ...

Scientists reverse Alzheimer's memory loss in mice by using NAD+ to restore brain energy, defying decades of research.

What happens when a promising therapy falls short? Medscape spoke with Jeffrey Cummings, MD, who led the EVOKE trials of the GLP-1 semaglutide for AD, about what the results mean — and what comes next ...

A team from the University of Barcelona has designed and validated in animal models an innovative compound with a pioneering mechanism of action for the treatment of Alzheimer's disease.

New treatments for neurodegenerative diseases like Alzheimer's, Parkinson's, and motor neuron disease (MND) could be unlocked thanks to microscopic medicines developed by researchers at the University ...

Rural Americans face higher Alzheimer's risk but often lack access to specialists and early diagnostic tools, prompting calls ...

After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

Research roundtable highlights early detection, biomarkers, interventions ...

Reviewed by Anton Porsteinsson, MD, Director of the University of Rochester Alzheimer’s Disease Care, Research and Education Program (AD-CARE) in New York; and the first William B. and Sheila Konar ...

Now, with the passing of House Bill 565, also known as Jill’s Law, all Mississippians will have access to biomarker testing ...